Tag: regenerative medicine company

March 13, 2019

NervGen Pharma Completes $10 Million Initial Public Offering; Shares to Commence Trading on TSX-V on March 15, 2019 – Symbol “NGEN”

NervGen Pharma Corp. ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of...
December 26, 2018

5 Top Medical Device News Stories of 2018

What was the top medical device news of 2018? Here's a list of our top headlines this year, according to...
November 28, 2018

Pluristem to Present First Cohort Data from PLX-R18 Hematological Study at ASH Annual Meeting

Pluristem Therapeutics (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that the company will...
October 16, 2018

U.S. FDA Approves Cost Recovery for PLX-PAD under Expanded Access Program in the Treatment of Critical Limb Ischemia

Pluristem Therapeutics (Nasdaq:PSTI;TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, and WideTrial a privately-held third-party sponsor...
September 25, 2018

Pluristem Therapeutics Announces FDA Orphan Drug Designation for PLX cell therapy

Pluristem Therapeutics (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that the U.S. Food...
September 18, 2018

Osiris Therapeutics Announces GrafixPL PRIME Launches October 1, 2018

Osiris Therapeutics (NASDAQ:OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announces...
April 20, 2018

Cynata Therapeutics Completes Patent Application to Cover Cymerus Stem Cell Technology

Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP) announced that it has completed the filing of a...